If you've been navigating a PMOS (PCOS) diagnosis and trying to conceive, you've probably come across myo-inositol. Maybe a friend mentioned it, your fertility clinic recommended it, or you found it at the bottom of a TikTok rabbit hole at midnight. Either way, you're right to be curious, because myo-inositol is one of the more genuinely evidence-backed supplements in the PCOS and fertility space.

A quick note on names: PCOS has been renamed PMOS (polyendocrine metabolic ovarian syndrome), and the NHS now uses the new name. We use both here while the change settles in. Here is what the rename means for you.

Want the wider picture on doses, side effects and what the guidelines say? Read our plain-English guide, Myo-Inositol Explained: Dose, Side Effects and the Evidence, alongside this article.

Short answer: myo-inositol has a solid, well-understood mechanism for supporting insulin sensitivity and ovulation in women with PCOS, and that part of the story holds up well. But some of the specific fertility-treatment claims in an earlier version of this article, several tied to a research cluster now under formal scrutiny for data-integrity issues, don't hold up the way we originally presented them. Here's the honest, corrected version: what myo-inositol actually does, what the cleanest available evidence says, where the research is genuinely still limited, and how to think about using it if you're trying to conceive with PCOS.

---

What Is Myo-Inositol, and Why Does It Matter for Fertility?

Myo-inositol is a naturally occurring compound found in virtually every cell in the body. It acts as a signalling molecule in the insulin pathway, which is why it matters for PCOS, a condition frequently driven by impaired insulin signalling.

It's often grouped with the B vitamins, though it isn't classed as an essential vitamin in the traditional sense. Your body produces some on its own, and you get more from foods like fruits, beans and wholegrains.

What makes it relevant to fertility is what it does inside your cells. Myo-inositol functions as what scientists call a "second messenger" in the insulin signalling pathway, essentially helping your cells respond to insulin properly. When that process breaks down, as it often does in PCOS, you end up with insulin resistance, and insulin resistance drives many of the condition's hallmark symptoms: irregular or absent ovulation, elevated androgens, weight changes, and disrupted egg development.

Supporting myo-inositol levels isn't about masking a symptom in isolation. It's aimed at one of the physiological mechanisms underneath several PCOS symptoms at once, which is part of why it's earned its reputation, even where, as you'll see below, some specific claims made about it elsewhere have been overstated.

---

---

Why Do Women With PMOS (PCOS) Have Lower Myo-Inositol Levels?

Research suggests women with PCOS may handle inositol differently within the ovaries, including a possible reduced ability to convert myo-inositol into its active form and higher urinary loss, which can leave the follicular environment relatively depleted.

Follicular fluid is the fluid that surrounds and nourishes developing eggs in the ovaries, and its composition has a direct bearing on egg quality. One proposed mechanism for PCOS is that some women convert less myo-inositol into its active form within the ovary itself, alongside excreting more of it in urine, resulting in a local deficiency right where it matters most for egg development.

This helps explain why having PCOS can affect fertility even in women who do manage to ovulate regularly, and why supporting insulin signalling matters beyond simply getting a period back.

---

What Does the Research Actually Say About Myo-Inositol and Fertility Treatment Outcomes?

We need to be direct with you here. An earlier version of this article cited a "meta-analysis" for a list of IVF outcome benefits that, on closer inspection, wasn't a real, checkable citation, and it doesn't reflect what the cleanest independent research currently shows.

Here's what happened. The previous version of this article claimed a body of research showed myo-inositol supplementation improved clinical pregnancy rates, reduced miscarriage, increased the proportion of high-quality embryos, reduced the number of degenerated or immature eggs retrieved, and lowered the amount of stimulation medication needed during IVF, all attributed to "a meta-analysis of myo-inositol in ART cycles" without naming a specific, verifiable paper.

When we went back and checked that claim properly, two things became clear. First, that citation as written cannot be verified. It doesn't point to a real, specific, checkable paper. Second, and more importantly, the actual independent research on this exact question doesn't support the claim as it was written. A 2017 systematic review and meta-analysis in Reproductive BioMedicine Online, looking specifically at myo-inositol in women with PCOS undergoing ICSI (a form of IVF), found myo-inositol supplementation was insufficient to improve oocyte quality, embryo quality or pregnancy rates. That's not a small discrepancy from what we'd previously written. It's close to the opposite conclusion.

A separate, more rigorous source backs this cautious picture up. In 2024, an international team of researchers published a systematic review and meta-analysis of inositol in PCOS to inform the 2023 update of the international evidence-based PCOS guidelines, a major undertaking that screened its input studies for data-integrity red flags and excluded several that didn't meet its standards. Its conclusion: the evidence for inositol's effect on pregnancy-related outcomes, including pregnancy rate, live birth and miscarriage, is currently "limited and inconclusive." Ovulation rate showed improvement in one comparison, but on low-certainty evidence.

We also want to be transparent about why this matters beyond a single wrong citation. Some of the earlier research behind myo-inositol and PCOS, including papers we'd previously relied on in this article, comes from a small cluster of researchers who have collectively accumulated more than a dozen retractions and formal expressions of concern since 2023, several specifically for undisclosed financial ties to companies manufacturing the inositol supplements being studied. One paper we had cited for a fertility claim has since been formally retracted for duplicated data. A second currently carries a live expression of concern. We've removed both, along with the unverifiable "meta-analysis" citation, and rebuilt this section around independent, integrity-screened evidence instead.

None of this means myo-inositol doesn't work. It means the strongest, most confident claims about IVF-specific outcomes were never as solid as we presented them, and the honest picture is more cautious: a promising, well-understood mechanism, genuine support for insulin sensitivity and ovulation, but currently limited and inconclusive evidence for pregnancy-rate and miscarriage-specific outcomes. We'd rather tell you that than repeat a figure that doesn't hold up.

---

How Does Myo-Inositol Support Egg Quality?

Myo-inositol supports the hormonal and metabolic environment eggs develop in, particularly FSH (follicle-stimulating hormone) signalling and insulin sensitivity within the ovaries, though exactly how much that translates into measurably better egg or embryo quality is still being clarified.

Here's the mechanism, broken down simply. FSH is the hormone responsible for stimulating egg growth in the ovaries. For FSH to do its job effectively, cells in the ovary need to respond to it properly, a response that depends partly on inositol-based signalling. When inositol is deficient, FSH signalling becomes less efficient, and eggs may not develop or mature as well as they should.

At the same time, insulin resistance in the ovarian environment can drive up androgen levels and disrupt the hormonal balance that healthy egg development depends on. Improving insulin sensitivity at the cellular level is one way myo-inositol may help restore that balance.

Some individual, smaller trials, including a double-blind trial in women with PCOS, have reported improvements in specific measures of oocyte maturity with myo-inositol supplementation. That's a real data point, but as above, the larger, integrity-screened evidence doesn't yet support confident claims that this reliably raises pregnancy or live birth rates. Egg quality and pregnancy outcome are related, not the same thing, and we won't conflate them.

---

Can Myo-Inositol Help if I'm Not Doing IVF?

Yes. Much of the original research was conducted in assisted-reproduction settings, but the underlying mechanisms, improved insulin sensitivity and more regular ovulation, apply to PCOS generally, regardless of how you're trying to conceive.

For women with PCOS trying to conceive naturally, the more consistently supported benefits are more regular menstrual cycles, more consistent ovulation, and improved insulin sensitivity, with downstream benefits for cycle regularity.

On the specific claim that women who weren't ovulating "began ovulating after three months of myo-inositol supplementation, without any additional fertility medications": we've reworded this deliberately. One of the studies we previously cited for it has since been retracted, and another is currently under a formal expression of concern, so we're no longer resting this claim on those sources. What we can say, based on the trial design we were able to independently verify, is that a meaningful majority, roughly two-thirds, of women taking myo-inositol alone did restore spontaneous ovulation, while the remaining share needed an added fertility medication to ovulate. That's still a genuinely useful result. It just isn't universal, and we don't want to imply that it is.

If you've been told your PCOS means conception will be difficult, that's worth knowing. It doesn't mean it will be easy for everyone. But it does mean there's something specific, mechanistically sound, and reasonably well-supported you can do to support your body, alongside your GP or fertility specialist, not instead of them.

---

What About Miscarriage? Does Myo-Inositol Help?

The honest answer is that we don't currently have strong evidence either way. The independent, integrity-screened research on inositol and pregnancy-related outcomes, including miscarriage, describes the evidence as limited and inconclusive, not as a demonstrated benefit.

Miscarriage risk is elevated in women with PCOS, partly because insulin resistance and PCOS-associated hormonal imbalances can affect early embryo development and implantation. Elevated LH levels, common in PCOS, have also been associated with higher miscarriage risk.

An earlier version of this article claimed myo-inositol supplementation reduces miscarriage rates, based on the unverifiable "meta-analysis" citation addressed above. We're removing that claim rather than softening it, because the best independent evidence currently available doesn't support it as stated. That's a genuinely disappointing thing to have to tell you, and we'd rather be straightforward about it than let a reassuring-sounding claim stand uncorrected.

What we can say honestly: myo-inositol's core mechanism, better insulin sensitivity and a healthier hormonal environment, is biologically plausible as a contributor to a lower-risk pregnancy, and it isn't associated with harm. But "biologically plausible" and "proven to reduce miscarriage" are different claims, and we won't collapse them into one just because the first sounds more reassuring.

---

What Is the Correct Dose of Myo-Inositol?

The most consistently used dose across the clinical research is 4g per day, typically split into two doses and taken alongside folic acid.

Some studies used higher doses, up to 12g per day, but 4g is the benchmark used across the majority of trials reviewed in the 2024 international PCOS guideline analysis, and it's the dose most consistently associated with improvements in insulin sensitivity and ovulation.

The folic acid pairing matters in its own right. Folic acid has a well-established role in preventing neural tube defects and supporting early fetal development, so including it alongside myo-inositol is both evidence-based and standard preconception practice, independent of any effect on myo-inositol's own action.

On timing, most trial protocols used continuous daily supplementation for a minimum of three months before assessing changes in ovulation or cycle regularity, with some continuing supplementation through a fertility treatment cycle. For natural conception, a minimum of three consistent months is a reasonable expectation before looking for cycle changes. The key word is consistent. Myo-inositol isn't a quick fix. It works by gradually supporting the cellular environment over time, which is how root-cause support tends to work.

How Long Does Myo-Inositol Take to Work?

The clearest trial data points to meaningful improvements in ovulation and cycle regularity after around three months of consistent supplementation, though some women notice earlier changes.

Three months is the rough minimum to see shifts in cycle regularity, ovulation, and hormonal markers like the LH/FSH ratio. Part of the reason it takes this long is biological: the egg development cycle, folliculogenesis, takes approximately 90 days, so you're supporting the environment eggs mature in across their full development window, not producing an overnight change.

---

Supporting Your Fertility Journey with MyOva's Preconception Supplement

This is exactly why myo-inositol is the foundation of MyOva's Preconception Supplement.

When I was doing my own research after my losses, I kept coming back to this compound. The mechanism made sense, and when I tried to find a quality, well-formulated version in the UK, I couldn't. That frustration, that moment of "why is this so hard?", is what sparked MyOva.

Our Preconception Supplement was formulated around the nutrients the research most consistently supports, not a scattershot of trendy ingredients. Alongside myo-inositol, it contains folate, CoQ10 (as ubiquinol), N-acetyl cysteine (NAC), alpha lipoic acid, L-arginine, vitamin D3, zinc, selenium, chromium, a full spread of B vitamins, vitamins C and E, beta-carotene, and magnesium, iron, iodine and copper.

Vitamin D3 contributes to normal function of the immune system and normal absorption of calcium and phosphorus. Zinc contributes to normal fertility and reproduction. Selenium contributes to normal function of the immune system. CoQ10, NAC, alpha lipoic acid and L-arginine don't carry authorised health claims of their own, but they're included for genuine research interest in egg quality, oxidative stress and reproductive wellbeing, not as overstated promises.

This isn't a supplement with a celebrity on the label. It's a formulation grounded in evidence, designed for women who want to understand what they're taking and why.

---

Are There Any Side Effects or Interactions to Know About?

Myo-inositol is generally well tolerated at doses used in research, up to 4g per day. The most commonly reported side effects in studies were mild gastrointestinal symptoms, bloating, nausea and loose stools, particularly when starting, and typically at higher doses.

Starting with a lower dose and building up over two to three weeks can help minimise this.

If you're currently taking metformin, it's worth mentioning myo-inositol to your doctor before starting. Both work on insulin sensitivity, and while they have complementary mechanisms and some research has looked at combined use, your prescribing clinician should be aware. The same applies to any other medication for blood sugar management.

Myo-inositol hasn't been shown to interact negatively with standard IVF protocols and is frequently recommended by fertility specialists and nutritional practitioners as part of IVF preparation, but always tell your clinic about any supplements you're taking.

---

What Are the Limitations of the Current Research, and Why Does That Matter?

Beyond the specific corrections above, the wider myo-inositol and PCOS literature has real, documented limitations, including a cluster of research-integrity concerns readers deserve to know about.

It would be disingenuous not to address this directly, especially after the corrections we've made above. Here's the fuller picture:

• A meaningful portion of the early clinical literature on myo-inositol and PCOS was produced by a small, overlapping group of researchers who have collectively accumulated more than a dozen retractions and expressions of concern since 2023, several specifically for undisclosed financial ties to companies manufacturing the inositol products being studied
• At least one previously well-cited trial in this space has been formally retracted for duplicated data, and another currently carries a live expression of concern
• Many individual trials, including some still considered broadly reliable, are relatively small, and some lacked proper blinding
• The majority of participants across the literature were Caucasian women, which limits how broadly the findings generalise
• There's real variability in the doses and durations used across studies, which makes direct comparison difficult
• Most research has focused specifically on women with PCOS undergoing fertility treatment; evidence in other fertility contexts is more limited

None of this means myo-inositol doesn't work, and it doesn't mean every study in this space is unreliable. Several of the trials we still cite below are from research groups outside the flagged cluster and haven't been retracted or questioned. But it does mean the field has genuine, ongoing integrity problems that deserve daylight rather than a footnote, and it's part of why we've deliberately anchored this article's core claims on the more rigorous, integrity-screened 2024 systematic review commissioned for the international PCOS guidelines, rather than on any single primary trial.

The mechanistic rationale for myo-inositol remains solid, the safety profile is good, and its role in supporting insulin sensitivity and ovulation is reasonably well supported. That's a reasonable basis for including it in a preconception plan, particularly for women with PCOS. But it should be part of a broader approach, not the entire strategy, and it shouldn't be oversold on pregnancy-specific outcomes the current evidence doesn't yet confidently support.

Nutrition, stress, sleep, movement and working with a knowledgeable healthcare provider all matter. Myo-inositol is a meaningful piece of the picture. It's not the whole picture.

---

---

Frequently Asked Questions

What does myo-inositol do for fertility?

It improves how cells respond to insulin and FSH, supporting better egg maturation and more regular ovulation. In women with PCOS, it helps address insulin resistance that often disrupts the cycle and affects egg development. The evidence for its effect on insulin sensitivity and ovulation is reasonably well supported; the evidence for pregnancy-specific outcomes like clinical pregnancy rate and miscarriage is currently limited and inconclusive, and we don't want to overstate that part.

How much myo-inositol should I take for PCOS and fertility?

The most commonly researched dose is 4g per day, typically split into two 2g doses and taken with folic acid. Most women use it for at least three months before expecting meaningful changes.

Can myo-inositol help if I'm not doing IVF?

Yes. The underlying mechanisms apply to all women with PCOS, including those trying to conceive naturally, and trial data suggests a majority, though not all, women who weren't ovulating restore spontaneous ovulation on myo-inositol alone.

Does myo-inositol reduce miscarriage risk?

We can't currently say that with confidence. An earlier version of this article claimed it did, based on a citation that didn't hold up. The best independent, integrity-screened evidence available describes pregnancy-related outcomes, including miscarriage, as limited and inconclusive, so we've removed that claim rather than repeat it.

Is myo-inositol safe during pregnancy?

Most research has focused on the preconception period and early fertility treatment. Some studies continued myo-inositol into the first trimester with no adverse effects noted, but if you're pregnant or have just found out you're pregnant, discuss ongoing supplementation with your midwife or GP.

How long does myo-inositol take to work?

The clearest trial data points to meaningful improvements in cycle regularity and ovulation after around three months of consistent supplementation, aligning with the roughly 90-day window of egg development. Some women notice changes earlier.

---

The Bottom Line on Myo-Inositol and Fertility

Myo-inositol isn't a miracle supplement, and we'll never tell you it is.

But for women with PCOS, particularly those dealing with insulin resistance, irregular cycles, or preparing for fertility treatment, it's one of the more mechanistically sound and reasonably evidence-backed nutritional interventions available for insulin sensitivity and ovulation. Where the evidence is genuinely still limited, on pregnancy-specific outcomes like clinical pregnancy rate and miscarriage, we'd rather tell you that plainly than let an overstated claim stand.

What I wish someone had told me, years before I worked this out for myself: you don't have to accept that PCOS automatically means your fertility is out of your hands, and you also don't have to accept every confident-sounding claim about a supplement at face value, including ones we've made ourselves in the past. Understanding your hormones, supporting your insulin sensitivity, and asking good questions about the evidence behind what you're taking are all things within your control.

You're not powerless. A diagnosis is a starting point, not a verdict, and neither is a single article, including this one.

If you'd like to explore whether the MyOva Preconception Supplement is right for where you are in your journey, it's formulated with myo-inositol at its core, alongside the comprehensive nutritional support the preconception period deserves.

Explore Related Hormone & PCOS Guides

• Myo-Inositol Explained: Dose, Side Effects and the Evidence
• PCOS and Insulin Resistance: What's Actually Going On in Your Body
• How to Improve Egg Quality: What the Evidence Actually Says
• The Truth About PCOS and Fertility: What Your GP Might Not Have Told You
• Preparing for IVF with PCOS: How to Support Your Body Before You Start
• Coffee and PCOS: What the Research Actually Shows

Health Disclaimer

The information in this article is for educational purposes only and is not intended to diagnose, treat, cure or prevent any condition, and should not replace advice from a qualified healthcare professional. Speak to your GP, midwife or fertility specialist before starting any new supplement, particularly if you are pregnant, breastfeeding, or undergoing fertility treatment.

References

1. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of Myo-Inositol in Women With PCOS: A Systematic Review of Randomized Controlled Trials. Gynecological Endocrinology. 2012;28(7):509-515.
2. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-Inositol in Patients With Polycystic Ovary Syndrome: A Novel Method for Ovulation Induction. Gynecological Endocrinology. 2007;23(12):700-703.
3. Ciotta L, Stracquadanio M, La Marca I, et al. Effects of Myo-Inositol Supplementation on Oocyte's Quality in PCOS Patients: A Double Blind Trial. European Review for Medical and Pharmacological Sciences. 2011;15(5):509-514.
4. Artini PG, Di Berardino OM, Papini F, et al. Endocrine and Clinical Effects of Myo-Inositol Administration in Polycystic Ovary Syndrome. A Randomized Study. Gynecological Endocrinology. 2013;29(4):375-379.
5. Pkhaladze L, Barbakadze L, Kvashilava N. Myo-Inositol in the Treatment of Teenagers Affected by PCOS. International Journal of Endocrinology. 2016;2016:1473981.
6. Fitz V, Graca S, Mahalingaiah S, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis to Inform the 2023 Update of the International Evidence-Based PCOS Guidelines. Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630-1655.
7. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for Subfertile Women With Polycystic Ovary Syndrome. Cochrane Database of Systematic Reviews. 2018;12:CD012378.
8. Mendoza N, Pérez L, Simoncini T, Genazzani A. Inositol Supplementation in Women With Polycystic Ovary Syndrome Undergoing Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reproductive BioMedicine Online. 2017;35(5):529-535.

References